drugset / Trial / NCT04871282
A Study of AL102 in Patients With Progressing Desmoid Tumors
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The current study is designed to evaluate the efficacy and safety of AL102 in patients with progressive desmoid tumors.
Timeline
- Start
- 2021-09-01
- Primary completion
- 2025-12-03
- Completion
- 2026-12
Outcome
Met primary endpoint
release “As previously reported, the RINGSIDE trial met its primary endpoint and all key secondary endpoints.” immunome.com ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | varegacestat | Small molecule | 1.2 mg | — |
| Subject | varegacestat | Small molecule | 2 mg | — |
| Subject | varegacestat | Small molecule | 4 mg | — |